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The term thrombophilia describes the predisposition to venous thromboembolism and, 
under certain circumstances, also an increased risk of arterial thrombosis. In a broad 
sense, thrombophilia includes any inherited or acquired disorder associated with an 
increased tendency to thrombosis. It was soon realised that thrombotic events have a 
complex multifactorial cause, usually a combination of genetic factors combined with 
acquired haematological disorders. Besides, behavioural factors, as diet or exercise, 
influence the incidence of thrombosis, making it difficult to asses the risk of thrombosis in a 
given individual. In any case, inherited thrombophilia is one of the main determinants of 
venous thromboembolism (VTE), and the presence of inherited thrombophilic defects 
exposes carriers to increased risks for VTE compared with non-carriers. The presence of 
hereditary thrombophilia should be considered in patients with a documented unexplained 
thrombotic episode or a positive family history. There is no clear relationship between 
clinical manifestations and the type of underlying thrombophilic defect. Thus, diagnosis of 
inherited thrombophilia has to be established on a laboratory basis. 
 
The concept that thrombophilia could be associated with a genetically determined 
hypercoagulable state was first proposed already in 1965 after the discovery of an 
association of thrombosis and antithrombin deficiency in a large family. Further 
studies in this field have gone in parallel with a better understanding of the components of 
blood coagulation, and the natural anticoagulant mechanisms essential in haemostasis, in 
particular the activated protein C pathway. In turn, these studies have lead to better 
therapies and protocols for the prophylactic control of thrombosis. Since the seminal work 
on antithrombin, genetic studies on thrombophilic families in combination with 
epidemiological studies lead to the discovery of anticoagulant protein deficits linked to 
thrombosis: protein C, protein S and antithrombin. These deficiencies are generally 
caused by a series of deleterious mutations in the respective genes behaving as relatively 
rare autosomal dominant genetic traits with a low or incomplete penetrance. Still, very few 
cases of thrombosis could be explained by these mechanisms. 
 
This situation changed with the discovery of activated protein C (APC) resistance in 1993 
and the mutation associated with factor V Leiden (FV)Leiden, and, shortly afterwards, the 
discovery of a mutation in the 3’ untranslated region of the prothrombin gene associated 
with increased concentration of prothrombin in plasma. Large epidemiological studies have 
confirmed that these mutations are risk factors for thrombophilia and opened the search 
for other thrombophilic traits. During the last decade, several additional prothrombotic risk 
factors have been described, including genetic variants and haplotypes associated with 
qualitative or quantitative defects of coagulation factor inhibitors, increased levels or 
function of coagulation factors, defects of the fibrinolytic system, altered platelet function, 
and hyperhomocysteinemia. At present, it is possible to identify an inherited predisposition 
to thrombosis in patients with such complications in about 50% to 80% of cases, 
depending on the study population. Nevertheless, despite the great number of mutations 
or polymorphisms which have been added to the list of candidate genetic traits implicated 
in thrombosis, the diagnosis of thrombophilia in most settings is still based on the 
“classical” parameters mentioned. In general, many of the genetic variants or haplotypes 
that have been recently studied are relatively common in the general population. These 
variants have been shown sometimes to be functional, i.e. they have an effect on the 
activity of the gene, but usually have only a minor impact on the thrombotic risk. 
Most of them are not interesting for diagnostic purposes, as they do not add significantly to 
the risk of thrombosis. In any case, genetic studies have provided insights into specific 
mechanisms of the coagulation cascade,which lead to thrombus formation as opposed to 
mechanisms of physiological haemostasis. 
 
The present set of articles in this Theme Issue are devoted to novel aspects of the 
mechanisms linked to thrombophilia, and nicely illustrate how the combination of 
biochemical and genetic studies have provided a substantial advance in our field. The first 
three articles discuss and summarise our knowledge about a candidate gene, each one 
found to be implicated in the risk of thrombosis. Mutations in the genes coding for factor V 
(F5) and protein S (PROS1) are well established as risk factors for thrombosis. Activated 
factor V is a cofactor of the prothrombinase complex essential in the exponential phase of 
thrombin production, but the discovery of factor V (FV)Leiden lead to the proposal of a new 
anticoagulant role for FV. Mutations in FV lead to an altered haemostatic balance, but 
manifest either as thrombotic or bleeding events. The article by Segers et al. describes 
how these functions are regulated and its implication in the aetiology of thromboembolic 
disease. As mentioned by the authors, FV variants are often found in combination with 
other prothrombotic factors in the same individual. Gene-gene interactions have been 
observed among the two alleles in F5, and mutations in the F5 gene as the FVLeiden 
could be combined with F5 haplotypes with a minor effect, as the F5 R2, to increase the 
risk of thrombosis. Besides these genetic interactions, acquired thrombotic traits could 
affect specifically FV, such as anti-FV auto-antibodies. 
 
A second chapter in this series focuses on PROS1, the gene coding for the vitamin K-
dependent anticoagulant protein S. Protein S deficiency has always been the most difficult 
to study among prothrombotic deficiencies, due to intrinsic difficulties 
in its diagnosis. Difficulties derive in part from the presence in plasma of two protein S 
pools, either as a free form, or in complex with C4 binding protein. Additionally, protein S 
has no direct enzymatic activity, acting as a modulator of serine proteases, either 
activating APC or directly inhibiting the prothrombinase complex, making it difficult to 
standardize an activity assay in plasma and to establish normal ranges for protein S 
assays in the general population. Despite these limitations, recent studies have raised the 
number of mutations associated with protein S deficiency (PSD) up to almost 200. 
Especially important have been the finding of large deletions in PROS1 in families were 
the initial genetic analysis was unable to find a causative mutation. Besides, the careful 
analysis of the mechanism associated with PSD has provided a better understanding of 
the relationship between the different kinds of PSD and the associated risk of thrombosis. 
New evidence support the concept that qualitative or mild quantitative deficiencies of 
protein S could play a role in thrombophilia, which could be important in certain 
populations. While these two articles focus on new aspects of the classical mechanisms of 
inherited thrombophilia, the following article in the series by Hernández-Espinosa et al. 
focuses on the serpin family of protease inhibitors and proposes new mechanisms leading 
to thrombosis that go beyond the genetic inheritance of 
deficiency. The atypical structure of serpins, the main direct inhibitors of thrombin and 
other serine proteases in plasma, makes this family of molecules especially sensitive to 
changes in environmental parameters such as pH or temperature. The concomitant effect 
of environmental and structurally de-stabilizing allelic variants could be the underlying 
cause of thrombosis associated with microbial infections. Furthermore, the described 
effect of certain drugs could also cause deficiency of haemostatic serpins that may be 
explained by conformational mechanisms. 
Interestingly, one of the latest components added to the natural anticoagulant pathways, 
the protein Z-dependent protease inhibitor (SERPINA10), belongs to the serpin family and 
it is actively studied as a candidate gene in thrombophilia. The article by Medina et al. 
reviews the interesting addition of a potentially important new candidate gene in the field of 
thrombosis. The discovery of a second protein C-binding protein in the endothelial cell 
membrane after thrombomodulin in 1995 added a new level of complexity to the APC 
anticoagulant system. The endothelial protein C receptor (EPCR) has been shown to have 
a major impact both in the activation and in the anticoagulant activity of APC. During 
recent years, a wealth of genetic data on the EPCR gene has supported its important role 
in maintaining haemostasis. From these studies, some of the polymorphisms and 
haplotypes found in the EPCR gene emerge as possible factors affecting the risk of 
thrombosis. The haplotypes in EPCR clearly correlate with the soluble concentration of 
EPCR in plasma.  
 
The last article in the present Theme Issue series studies a different aspect of the 
relationship between genetic variants and thrombosis, in this case not as a causative 
mechanisms underlying thrombosis. The article by Oldenburg et al. focuses on the effect 
of common genetic variants in the efficacy of the oral anticoagulant therapy. For some 
years it has been known that the oral anticoagulants could have broad differences in their 
effect. While some of the differences are clearly related to diet and other behavioural 
factors, there was also a genetic component in these differences, as was proved when 
genetic variants in the cytochrome P450 CYP2C9 were shown to affect the efficacy of oral 
anticoagulants. The discovery of the target enzyme for oral anticoagulants, VKORC1, and 
genetic studies determining the effect of different haplotypes of the gene with the efficacy 
of oral anticoagulants has lead to the conclusion that VKORC1 is the most important 
determinant of efficacy of the anticoagulant treatment. This discovery was important for 
establishing better dosing schemes for patients on anticoagulation, and therefore has had 
a direct consequence in clinical practice. 
 
All the articles in the series are good examples of how genetic studies have shown the 
way for a better understanding of thrombosis and how to treat it. Still, it is a matter of 
intense debate under which circumstances genetic screening for thrombophilia are useful 
in clinical practice, as it seems advisable that it should be performed only in cases where 
such testing is likely to influence patient management, as it is clearly illustrated in the last 
article of the series. Furthermore, the knowledge obtained from the association of genetics 
and thrombotic disease has been central in establishing our present paradigm of 
haemostasis and its associated diseases. 
 
